Skip to main content
IRLAB Therapeutics logo

IRLAB Therapeutics — Investor Relations & Filings

Ticker · IRLAB ISIN · SE0012675361 LEI · 549300JAT34LHEI0DH60 ST Manufacturing
Open in API
Filings indexed 156 across all filing types
Latest filing 2026-05-06 Interim / Quarterly Rep…
Country SE Sweden
Listing ST IRLAB

About IRLAB Therapeutics

https://irlab.se/

IRLAB Therapeutics is a research and development company that discovers and develops novel treatments for neurodegenerative diseases, with a primary focus on Parkinson's disease and other central nervous system (CNS) disorders. The company's research originates from Nobel Prize-winning science and is driven by its proprietary Integrative Screening Process (ISP) platform. This systems pharmacology-based discovery engine utilizes an extensive database to generate a pipeline of drug candidates. The company's portfolio includes clinical-stage assets such as Mesdopetam (IRL790), in development for treating levodopa-induced dyskinesia (LIDs), and Pirepemat (IRL752), which is being developed to reduce falls and improve balance in patients with Parkinson's disease.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport januari – mars 2026' which translates to 'Interim Report January – March 2026'. It contains detailed financial data for the first quarter of 2026, including net sales, operating results, earnings per share, cash flow, and employee numbers. It also includes management commentary, strategic priorities, and operational updates. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The content is consistent with a quarterly or interim financial report providing substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-06 English
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report January – March 2026' and contains detailed financial data for the first quarter of 2026, including net sales, operating profit, earnings per share, cash flow, and other financial metrics. It also includes management commentary, strategic priorities, and updates on clinical studies and partnerships. The presence of comprehensive financial statements and substantive analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document length (15,000 characters) and content confirm it is the report itself, not merely an announcement or certification. Therefore, the appropriate classification is 'IR' for Interim / Quarterly Report. Q1 2026
2026-05-06 English
KALLELSE TILL EXTRA BOLAGSSTÄMMA I IRLAB THERAPEUTICS AB
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice and agenda for an Extraordinary General Meeting (EGM) of IRLAB Therapeutics AB, including instructions for shareholders on how to participate and vote, proposals for amendments to the articles of association, and decisions regarding new share issues (rights issue and directed issue). It contains no financial statements or financial performance data but focuses on corporate governance matters and capital raising decisions to be approved by shareholders at the meeting. This type of document is a formal meeting notice and agenda, which fits the category of Proxy Solicitation & Information Statement (PSI), as it provides information to shareholders to solicit votes for the meeting. It is not an announcement of voting results (DVA), nor a full annual or interim report, nor a capital/financing update announcement (CAP) since it is a meeting notice with proposals rather than a post-event update. Therefore, the correct classification is PSI with high confidence.
2026-05-05 English
KALLELSE TILL EXTRA BOLAGSSTÄMMA I IRLAB THERAPEUTICS AB
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice and agenda for an Extraordinary General Meeting (Extra Bolagsstämma) of IRLAB Therapeutics AB, including instructions for shareholders on how to participate and vote, proposals for amendments to the articles of association, and decisions regarding new share issues (nyemission) with and without preferential rights. The content focuses on calling the meeting, the agenda items, and detailed proposals for capital increases and share issuance. There are no financial statements, earnings data, or management discussion of financial results. The document is not a report but a formal meeting notice and proposal document for shareholder approval of capital changes and board matters. This fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings, especially for extraordinary meetings involving capital changes and board elections.
2026-05-05 English
IRLAB resolves on a rights issue of approximately SEK 68 million with an overallotment issue and obtains extended loan financing
Capital/Financing Update Classification · 95% confidence The document is a press release from IRLAB Therapeutics dated May 5, 2026, announcing a rights issue of approximately SEK 68 million, an overallotment issue, and extended loan financing. It details the terms of the rights issue, subscription undertakings, use of proceeds, and background on the company's drug candidates. The content focuses on capital raising activities, financing updates, and shareholder subscription rights. There are no financial statements or detailed financial performance data presented, nor is this a transcript, management report, or legal proceeding update. The document is clearly an announcement of a capital raising event and financing update, fitting the Capital/Financing Update category. The document length is substantial and contains detailed information about the financing but is not a full financial report or annual/interim report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2026-05-05 English
IRLAB beslutar om företrädesemission om cirka 68 MSEK med övertilldelningsemission samt erhåller förlängd lånefinansiering
Capital/Financing Update Classification · 95% confidence The document is a press release dated May 5, 2026, from IRLAB Therapeutics AB announcing a rights issue (företrädesemission) of approximately 68 million SEK with an overallotment option and an extension of loan financing. It details the terms of the rights issue, subscription commitments, use of proceeds, and background on the company and its projects. The document is a detailed announcement about a capital raising event, including subscription terms, investor commitments, and loan refinancing. It does not contain financial statements or quarterly results but focuses on financing activities and capital structure changes. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is not merely a brief announcement or a report publication announcement. Hence, the classification is CAP with high confidence.
2026-05-05 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.